 |
|
|
| |
Interferon-free Regimen Containing Setrobuvir in Combination with Ritonavir-boosted Danoprevir and Ribavirin with or without Mericitabine in HCV Genotype 1 Treatment-naive Patients: Interim Results from the ANNAPURNA Study
|
| |
| |
Reported by Jules Levin
AASLD 2013 Nov 1-4 Wash DC
D.M. Jensen,1 M. Brunda,2 R. Elston,3 E.J. Gane,4 J. George,5 K. Glavini,3 J.M. Hammond,6 S. Le Pogam,2 I. Najera,2 S. Passe,2 A. Piekarska,7 I. Rodriguez,2 S. Zeuzem,8 T. Chu;2 on behalf of the ANNAPURNA study investigators
1University of Chicago Medicine, Chicago, IL, USA; 2Hoffmann-La Roche Inc, Nutley, NJ, USA; 3Roche Products Ltd, Welwyn, United Kingdom; 4Auckland Clinical Studies, Grafton, New Zealand; 5Storr Liver Unit, Westmead Hospital and University of Sydney, Westmead, NSW, Australia; 6F. Hoffmann-La Roche Ltd, Basel, Switzerland; 7Department of Infectious Diseases and Hepatology, Medical University of Lodz, Lodz, Poland; 8Medizinische Klinik I, Johann-Wolfgang-Goethe University Hospital, Frankfurt, Germany
|
| |
|
|
|
|
|
